OmniAb, Inc. is a biotechnology enterprise that focuses on discovering and developing next-generation therapeutic antibodies to support global drug development initiatives. The organization provides its partners—ranging from mid-sized biotech firms to major international pharmaceutical companies—with access to proprietary biological intelligence creation engines, including specialized transgenic animal platforms that generate optimized antibodies. By utilizing these advanced discovery tools, researchers can efficiently identify and validate high-quality antibody candidates targeting complex human diseases across oncology, immunology, and various therapeutic areas. OmniAb operates primarily through a collaborative business model, earning revenues through technology access fees, milestone payments tied to clinical progress, and downstream royalties upon successful commercialization of partner-developed drugs.